Balyasny Asset Management
NVCR icon

Balyasny Asset Management’s NovoCure NVCR Stock Holding History

Balyasny Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-83,500
Closed -$1.35M – 2775
2023
Q3 		$1.35M Buy
83,500
+20,800
+33% +$600K ﹤0.01% 1491
2023
Q2 		$2.6M Buy
+62,700
New +$3.89M 0.01% 1294

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Balyasny Asset Management's NVCR Position: Q1 2026 in Review

Balyasny Asset Management reduced its NovoCure (NVCR) stake by 62% in Q1 2026, selling an estimated $244K and leaving 11,831 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Balyasny Asset Management first reported a position in NVCR in Q1 2018 and has held it in 21 quarters since. The position peaked at $40.4M in Q2 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Balyasny Asset Management held 11,831 shares of NovoCure worth $129K as of Q1 2026.
  • Balyasny Asset Management sold 19,508 NovoCure shares in Q1 2026, an estimated $244K.
  • NovoCure made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2744 holding.
  • Balyasny Asset Management first reported a position in NovoCure in Q1 2018 and has held it in 21 quarters since.
  • Balyasny Asset Management's NovoCure position peaked at $40.4M in Q2 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.